finance.yahoo.com ·
Invivyd Ivvd 10 Best Nasdaq
Topic context
This topic has been covered 413454 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedInvivyd is a small-cap biotech with one approved COVID-19 antibody (PEMGARDA) generating modest revenue. The company is burning cash on R&D for next-gen COVID and other infectious disease antibodies. No supply chain or commodity impact; commercial mechanism is weak — revenue growth is small, pipeline is early-stage, and no partnership or manufacturing scale-up announced. Sector PHARMA_BIOTECH is relevant due to the company's primary business, but the commercial signal is low.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Invivyd Q1 2026 net product revenue $13.7M, +22% YoY
- Cash balance $184.2M at quarter end
- R&D expenses $30.7M, net loss $41.4M
- DECLARATION Phase 3 trial for VYD2311 fully enrolled, top-line data Q3 2026
- Advancing measles and RSV programs, IND readiness by late 2026
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
nbclosangeles.com
Spacex Confirms Plans for IPO
manilatimes.net
Auddia Submits S 4 for Merger With Thramann Holdings Establishing Mccarthy Finney as a Unified AI Platform
zerohedge.com